<i>FGFR1</i> Amplification Drives Endocrine Therapy Resistance and Is a Therapeutic Target in Breast CancerNicholas C. Turner, Alan Ashworth, Alex Pearson et al.|Cancer Research|2010Cited by 740
Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targetsNicholas C. Turner, Jorge S. Reis‐Filho, Maryou B. Lambros et al.|Oncogene|2010Cited by 416
FGFR Signaling Promotes the Growth of Triple-Negative and Basal-Like Breast Cancer Cell Lines Both <i>In Vitro</i> and <i>In Vivo</i>Rachel Sharpe, Nicholas C. Turner, Alex Pearson et al.|Clinical Cancer Research|2011Cited by 170
Functional Viability Profiles of Breast CancerRachel Brough, Alan Ashworth, Jessica Frankum et al.|Cancer Discovery|2011Cited by 143
Integrative molecular and functional profiling of ERBB2-amplified breast cancers identifies new genetic dependenciesAlan Ashworth, Daniel Wetterskog, Alan Mackay et al.|Oncogene|2013Cited by 24